Radioactive Iodine Ablation for Graves Disease in 2019
RAI therapy is a highly effective and safe first-line treatment option for Graves' disease, with a typical single dose of 10-15 mCi (370-555 MBq) administered to achieve permanent hypothyroidism, which is the intended therapeutic goal. 1
Treatment Modality Selection
Graves' hyperthyroidism can be treated with three equally acceptable modalities: RAI therapy, antithyroid drugs (methimazole), or thyroidectomy 1. The choice depends on patient-specific factors including severity of hyperthyroidism, presence of ophthalmopathy, comorbidities, and patient preference.
Pre-Treatment Preparation
Risk Stratification and Beta-Blockade
- All patients with severe thyrotoxicosis (extremely symptomatic OR free T4 levels 2-3× upper limit of normal) require beta-adrenergic blockade before RAI 1
- Beta-blockers should also be given to elderly patients, those with resting heart rate >90 bpm, or cardiovascular disease 1
Methimazole Pretreatment
Consider methimazole pretreatment in high-risk patients (severe symptoms, markedly elevated free T4, elderly, significant comorbidities including cardiovascular disease, atrial fibrillation, heart failure, or diabetes) 1. If used, discontinue methimazole 3-5 days before RAI, restart 3-7 days after, and taper over 4-6 weeks 1.
Important caveat: One dissenting view notes that methimazole pretreatment may reduce RAI efficacy and is not always necessary 1.
Mandatory Pre-Treatment Steps
- Pregnancy test within 48 hours before RAI in all women of childbearing potential—verify negative result before proceeding 1
- Optimize all comorbid conditions medically before RAI administration 1
RAI Dosing Strategy
Administer sufficient radiation in a single dose (typically 10-15 mCi or 370-555 MBq) with the explicit goal of rendering the patient hypothyroid 1. This approach achieves:
- 69% hypothyroidism rate at 1 year with 10 mCi 1
- 75% hypothyroidism rate at 6 months with 15 mCi 1
90% overall success rate 2
Recent evidence suggests that when using fixed dosing without uptake studies, doses ≥14.8 MBq per gram (≥0.4 mCi/g) of thyroid tissue achieve optimal response rates 3. Doses of 14.8-18.1 MBq/g (0.4-0.5 mCi/g) maximize response without added benefit from higher doses 3.
Special Consideration: Graves' Ophthalmopathy (GO)
No or Inactive GO
RAI, methimazole, and thyroidectomy are equally acceptable options 1. RAI without corticosteroids is appropriate 1.
Mild Active GO Without Risk Factors
All three treatment modalities remain equally acceptable 1.
Mild Active GO With Risk Factors (Smoking, Others)
If RAI is chosen, concurrent corticosteroids are mandatory 1. Recommended regimen: prednisone 0.4-0.5 mg/kg/day starting 1-3 days after RAI, continued for 1 month, then tapered over 2 months 1. Lower doses (0.2 mg/kg/day for 6 weeks) may be equally effective for mild disease 1.
Moderate-to-Severe or Sight-Threatening Active GO
Avoid RAI—use methimazole or surgery instead 1. If RAI is absolutely necessary, concurrent high-dose corticosteroids are required 1.
Critical pitfall: Smoking significantly increases GO risk with RAI. All patients must be counseled about smoking cessation 1, 4.
Post-Treatment Monitoring
- Assess free T4 and total T3 at 1-2 months after RAI 1
- If thyrotoxic, continue monitoring every 4-6 weeks 1
- Retreatment with RAI is indicated if:
- Hyperthyroidism persists at 6 months, OR
- Minimal response at 3 months 1
- Most patients (90.4%) respond within 6 months, with faster response (13.9 vs 17.5 weeks) when adequate doses per gram are used 3
Radiation Safety
Provide written radiation safety precautions to all patients 1. If precautions cannot be followed, select alternative therapy 1.
Safety Profile
RAI does not increase all-cause mortality, cardiovascular mortality, major cardiovascular events, or cancer risk—it may actually reduce these risks when hypothyroidism is promptly achieved 2. The de novo GO incidence is approximately 5-8% in recent cohorts, predominantly in high-risk individuals who did not receive steroid prophylaxis 4. RAI does not permanently impair fertility or cause offspring abnormalities 2.